Evidence map›Paper›PMID 40677245›Full record

ReviewComputational and structural biotechnology journal2025

Bacteriophage-based strategies for biocontrol and treatment of infectious diseases.

Trinh Thi Trang Nhung, Swati Verma, Saravanaraman Ponne, Gautam Kumar Meghwanshi, Thomas Schön, Rajender Kumar

Abstract readReview
In one paragraph

Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Trinh Thi Trang NhungFaculty of Biomedical Sciences, Phenikaa University, Yen Nghia, Ha Dong, Hanoi 12116, Vietnam.
Swati VermaDepartment of Industrial Biotechnology, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of Technology, Stockholm, Sweden.
Saravanaraman PonneDepartment of Medical Biotechnology, Aarupadai Veedu Medical College and Hospital, Vinayaka Mission's Research Foundation (Deemed to be University), Puducherry 607403, India.
Gautam Kumar MeghwanshiDepartment of Microbiology, M.G.S. University, Bikaner, India.
Thomas SchönDepartment of Infectious Diseases, Kalmar County Hospital, Linköping University, Kalmar, Sweden.
Rajender KumarDepartment of Biomedical and Clinical Sciences, Division of Infection and Inflammation, Linköping University, Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacteriophages are viruses that infect bacteria, which are essential for controlling bacterial diversity. Among the novel aspects, phage display-based strategies are used for epitope mapping and the development of immunotherapy. A recent classification system has been developed based on the recent sequencing methods and bioinformatic tools. The unique specificity of phages is of increasing use in biocontrol, where bacteriophages are applied to target and reduce harmful bacterial populations in agriculture, food preservation and safety, offering a sustainable alternative to chemical exposure and a plausible solution to excessive misuse of antibiotics. Phage therapy has emerged as a complement to antibiotics for difficult-to-treat infectious diseases such as multi-drug resistant bacteria where other alternatives are lacking. The ability of bacteriophages to specifically target pathogenic bacteria while sparing the normal flora makes them attractive treatment options. Among the challenges are the slow uptake of phage therapy in the clinical setting, a lack of standardisation and regulatory issues. Nevertheless, phage-based strategies are likely to become a future cornerstone for biocontrol and treatment of infectious diseases.

Indexed as

Antimicrobial resistanceBacteriophageBiocontrolPhage therapy and antibiotic

Identifiers

PMID40677245
PMCPMC12270615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.